CCDC97 Inhibitors
CCDC97 inhibitors encompass a group of compounds that target various signaling pathways implicated in the regulation of CCDC97 activity. Rapamycin and Torin 1, as mTOR inhibitors, directly suppress the mTORC1 and mTORC2 complexes, respectively. Given that mTOR signaling is critical for a variety of cellular processes that could include the stability and function of CCDC97, the inhibition of mTOR by these compounds would lead to a less conducive environment for CCDC97 activity. The assumption here is that CCDC97 requires mTOR-mediated phosphorylation for its function; therefore, the inhibition of mTOR would lead to a direct reduction in CCDC97 activity.
Furthermore, compounds like Wortmannin and LY294002, which are PI3K inhibitors, and PD98059 and U0126, which are MEK inhibitors, target upstream kinases within the PI3K/AKT and MAPK/ERK pathways, respectively. The inhibition of these kinases would result in decreased activation of downstream targets that may include CCDC97. If CCDC97's activity is contingent upon signaling through these pathways, such as through AKT-mediated or ERK-mediated phosphorylation, then these inhibitors would lead to a decrease in CCDC97 function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that blocks the mTORC1 complex, which is essential for protein synthesis and cell growth. By inhibiting this pathway, Rapamycin would impair the cellular environment that CCDC97 needs for its function if CCDC97 relies on mTORC1 activity for its stabilization or interaction with other proteins. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Selective mTOR inhibitor that targets both mTORC1 and mTORC2 complexes. Inhibition of these complexes would prevent the phosphorylation events necessary for CCDC97 activity, assuming CCDC97 requires mTOR-mediated phosphorylation for its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that blocks the PI3K/AKT pathway, leading to decreased activation of AKT. If CCDC97's activity is contingent upon AKT-mediated signaling events, Wortmannin would suppress CCDC97's function by disrupting this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor, similar to Wortmannin, LY294002 would also reduce AKT activity. This would indirectly lead to the inhibition of CCDC97 if it is regulated by or dependent on the PI3K/AKT pathway for its functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that blocks the MAPK/ERK pathway. By inhibiting this pathway, PD98059 would indirectly inhibit CCDC97 if its activity or stability is regulated by the MAPK/ERK signaling cascade. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK1/2 inhibitor that also targets the MAPK/ERK pathway. U0126 would lead to decreased activation of ERK, and if CCDC97 is activated or stabilized by ERK-mediated signaling, its activity would be inhibited. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that would impede the p38 MAPK signaling pathway. By doing so, SB203580 could inhibit CCDC97 if it is involved in cellular responses mediated by p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that would disrupt the JNK signaling pathway. If CCDC97's function is modulated by JNK activity, SP600125 would result in decreased functional activity of CCDC97. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that prevents the degradation of ubiquitinated proteins. If CCDC97 is normally regulated by proteasomal degradation, Bortezomib would lead to its accumulation, potentially disrupting normal function by perturbing the protein degradation system. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor similar to Bortezomib, MG132 would also cause the accumulation of CCDC97 if it is normally targeted for degradation by the proteasome, thus potentially inhibiting its regular function. | ||||||